1-(4-Fluoro-3-methylphenyl)-N-methylmethanamine | 381236-52-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Fluoro-3-methylphenyl)-N-methylmethanamine
• CAS: 381236-52-8
• 化学式: C₉H₁₂FN
• mdl: MFCD12779982
• 分子量: 153.2
• InChiKey: HEBLGAUCTCTJOI-UHFFFAOYSA-N

物化性质

• 沸点：
  198.2±25.0 °C(Predicted)
• 密度：
  1.010±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE
  申请人：JIANGSU KANION PHARMACEUTICAL CO. LTD

  公开号：US20170066732A1

  公开（公告）日：2017-03-09

  Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof; and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.

  揭示了一种新型抗肠道病毒71（EV71）1,2,5-噻二唑啉-1,1-二氧化物衍生物或其药用盐；具体而言，是由式（II）表示的化合物或其药用盐。
• ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS
  申请人：HUMANWELL HEALTHCARE (GROUP) CO., LTD.

  公开号：US20170029430A1

  公开（公告）日：2017-02-02

  Disclosed is a series of analogues of 4H-pyrazolo[1,5-α]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

  公开了一系列4H-吡唑并[1,5-α]苯并咪唑化合物的类似物作为PARP抑制剂。特别是，发明中公开了如公式(I)所示的化合物或其药用可接受的盐作为PARP抑制剂。
• HIV integrase inhibitors
  申请人：——

  公开号：US20030181490A1

  公开（公告）日：2003-09-25

  The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the formula 1 wherein R 1 is C 1 -C 4 alkyl, carbocyclic radical, heterocyclic radical, aryl-C 1 -C 2 alkylene, aryloxy-C 1 -C 2 alkylene, alkoxy-CC(O)—, wherein R 1 is optionally substituted from 1-3 times with halo, C 1 -C 2 alkyl or C 1 -C 2 alkoxy, or R 1 is H; R 2 is H or C 1 -C 4 alkyl; R 3 is H, C 1 -C 4 alkyl or phenyl-C 0 -C 2 alkylene which is optionally substituted with 1-3 R 5 ; R 4a is carbocylic radical, heterocyclic radical, aryloxy, aryl-C 1 -C 4 alkylene, aryl-cyclopropylene, aryl-NHC(O)—, wherein R 4a is optionally substituted with 1-3 R 5 ; and wherein each R 5 is independently selected from H, halo, C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, R 6 -phenyl, R 6 -phenoxy, R 6 -benzyl, R 6 -benzyloxy, NH 2 C (O)—, alkyl-NHC(O)—, wherein R 6 is H, halo; Z is a bond or a substituted or unsubstituted C 1 -C 4 alkylene group; and B 2 is 2

  本发明涉及抑制HIV整合酶的化合物，并通过给予式1中的化合物治疗艾滋病或ARC，其中R1为C1-C4烷基，碳环基，杂环基，芳基-C1-C2烷基，芳氧基-C1-C2烷基，烷氧基-CC（O）-，其中R1可以用卤素，C1-C2烷基或C1-C2烷氧基从1-3次取代，或R1为H；R2为H或C1-C4烷基；R3为H，C1-C4烷基或苯基-C0-C2烷基，该苯基-C0-C2烷基可以选择性地用1-3个R5取代；R4a为碳环基，杂环基，芳氧基，芳基-C1-C4烷基，芳基环丙基，芳基-NHC（O）-，其中R4a可以选择性地用1-3个R5取代；每个R5都是独立选择的H，卤素，C1-C4烷基，C1-C4烯基，C1-C4卤代烷基，C1-C4烷氧基，R6-苯基，R6-苯氧基，R6-苄基，R6-苄氧基，NH2C（O）-，烷基-NHC（O）-，其中R6为H，卤素；Z为键或取代或未取代的C1-C4烷基；B2为2。
• IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEREOF IN PREPARATION OF MEDICAMENT
  申请人：Medshine Discovery Inc.

  公开号：EP3081569A1

  公开（公告）日：2016-10-19

  Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.

  本发明公开了一种抗病毒化合物及其在制备治疗病毒感染的药物中的用途。具体而言，本发明涉及一种用于治疗呼吸道合胞病毒感染的咪唑衍生物。